Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25175239 | 0.89 | MAPT (0.55) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL25176060 | 0.85 | MAPT (0.60) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL10035934 | 0.84 | POLB (0.59) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL25169674 | 0.84 | MAPT (0.66) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL18296386 | 0.82 | MAPT (0.59) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL25447160 | 0.82 | GFER (0.53) | MAPTPOLBALDH1A1LMNACYP2C9 | |
| SCHEMBL21526566 | 0.81 | MAPT (0.58) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL15896472 | 0.80 | MAPT (0.72) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL25197695 | 0.78 | POLB (0.67) | MAPTPOLBSIRT6ALDH1A1LMNA | |
| SCHEMBL7293116 | 0.77 | MAPT (0.54) | MAPTPOLBSIRT6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | MAPT 2440/4885POLB 698/4885SIRT6 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.